Advertisement

Search Results

Advertisement



Your search for ASCO Chief Executive Officer Clifford A. Hudis, MD, FACP, FASCO matches 91 pages

Showing 51 - 91


WebMD Recognizes Seven Cancer Innovators With Its Health Heroes Award

On January 15, 2019, WebMD, an online and print health-care resource for consumers, presented its 2018 Health Heroes Award in New York City to 7 people who are making a difference in oncology care. The honorees include Karen M. Winkfield, MD, PhD, Associate Professor of Radiation Oncology at Wake...

issues in oncology

ASCO Statement on the Effect of Lower Drug Costs on People With Cancer

Clifford A. Hudis, MD, FACP, FASCO, ASCO Chief Executive Officer, on the effects of lower drug costs on people with cancer: While ASCO supports efforts to control drug prices, we are keenly aware that optimal cancer care requires patient access to the most medically appropriate drug, at the most...

MD Anderson President Emeritus, John Mendelsohn, MD, Dies at Age 82

John Mendelsohn, MD, President Emeritus of The University of Texas MD Anderson Cancer Center, died of glioblastoma on January 7, 2019, at his home in Houston at age 82. He was an internationally acclaimed leader in the field of medicine and scientist whose research helped pioneer a new type of...

Scientific and Career Development Retreat: Networking and Collaborating With Promising Researchers

ASCO’s Conquer Cancer Foundation is committed to supporting the research and career development of young researchers through its Grants & Awards Program. On October 10–11, 2018, Conquer Cancer hosted its 4th Scientific and Career Development Retreat at ASCO headquarters in Alexandria,...

A Career Path Shaped by Unlimited Possibilities for Clifford A. Hudis, MD, FACP, FASCO

In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, interviewed Clifford A. Hudis, MD, FACP, FASCO, ASCO’s Chief Executive Officer. Prior to his current position, Dr. Hudis served in a variety of roles at ASCO, including President during ASCO’s 50th anniversary...

Meet Your ASCO President-Elect, Dr. Howard A. ‘Skip’ Burris

Howard A. “Skip” Burris III, MD, FACP, FASCO, a long-time ASCO member and volunteer, began his role as ASCO President-Elect in June 2018. An ASCO member for nearly 30 years, Dr. Burris’ service to the Society is extensive. His volunteer roles include member of the ASCO Board of Directors and...

Cory Wiegert Named New CEO of CancerLinQ LLC

Cory Wiegert has been named Chief Executive Officer (CEO) of CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO. Mr. Wiegert, a proven expert in building and successfully launching innovative technology solutions, began his new role today (August 13, 2018), overseeing the continued...

ASCO, ABIM Collaborate on Pathway to Maintenance of Board Certification

ASCO and the American Board of Internal Medicine (ABIM) have announced that they are working to co-create a pathway to provide doctors with a flexible way to maintain board certification. The work with ASCO reflects real progress in ABIM’s efforts to collaborate with medical societies. Beginning in ...

Serving as ASCO President Is One of the Best Jobs in the World

The opportunity to serve as ASCO President is the greatest honor of my professional career. It has been a pleasure and a highly rewarding experience to interact with our members and members of ASCO’s Board, executive leadership, and professional staff during my tenure. The year has allowed me to...

ASCO and ABIM Announce Collaboration on Maintenance of Certification Pathway

ASCO and the American Board of Internal Medicine (ABIM) have announced that they are working to co-create a pathway to provide doctors with a flexible way to maintain board certification. Beginning in 2020, oncologists will be able to choose from two different assessment pathways. They may take an ...

State-Level Cancer Policy Priorities, Advocacy Discussed in Statehouses and on ASCO in Action Podcast

WITH THE MAJORITY of state legislatures currently in session, ASCO and state societies across the country continue to work together to ensure lawmakers understand how legislation impacts the cancer care delivery system.  For example, in Rhode Island and Washington, ASCO worked with the Rhode Island ...

ASCO Hosts Inaugural State of Cancer Care in America Event to Examine Issues in Precision Medicine

Precision medicine is changing cancer care in profound ways. It is expected that the number of patients who benefit from precision medicine will continue to increase in the coming years, as treatments become more effective and research yields more insights on patient populations who are most likely ...

immunotherapy

Encourage Patients To Promptly Report Immunotherapy Side Effects

Physicians can be proactive in alerting patients to possible adverse effects of immunotherapy and in encouraging patients to report them. “It is important to emphasize that whenever a patient develops a new symptom, always considering that this might be an immune-related side effect. We need to...

solid tumors
immunotherapy

ASCO Names CAR T-Cell Immunotherapy Its Clinical Advance of the Year

This past January, ASCO published Clinical Cancer Advances 2018,1 its 13th annual report on the progress being made against cancer. The report names chimeric antigen receptor (CAR) T-cell immunotherapy as ASCO’s Advance of the Year. In 2017, the U.S. Food and Drug Administration (FDA) approved two ...

ASCO, NCCN Provide Guidance on Understanding and Managing Immunotherapy Side Effects

Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer. By unleashing the body’s immune system to attack cancer, these treatments can send even the most hard-to-treat cancers into...

ASCO in Action’s New Podcast Series Addresses Critical Cancer Policy and Practice Issues

IN JANUARY 2018, ASCO launched the ASCO in Action Podcast, a new podcast series hosted by ASCO Chief Executive Officer Clifford A. Hudis, MD, FACP, FASCO. This series features thought leaders and experts in oncology discussing the most pressing policy and practice issues impacting the cancer care...

supportive care
symptom management
immunotherapy

ASCO and NCCN Provide Guidelines for Managing Immunotherapy Side Effects

Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer. By unleashing the body's immune system to attack cancer, these treatments can send even the most hard-to-treat cancers into...

Highlights From the Conquer Cancer Foundation’s Third Annual Career Development Retreat

The Conquer Cancer Foundation of ASCO is committed to supporting the research and career development of young researchers through its Grants & Awards Program. In October 2017, Conquer Cancer hosted its third Scientific and Career Development Retreat at ASCO Headquarters in Alexandria,...

issues in oncology

Link Between Cancer and Diabetes, High Body Mass Index

According to the International Agency for Research on Cancer and the World Cancer Research Fund, there is a causal association between a high body mass index (BMI) and 14 cancers, including colorectal, gallbladder, pancreatic, kidney, liver, endometrial, postmenopausal breast, ovarian, gastric...

ASCO Offers Path to Addressing Affordability of Cancer Drugs

ASCO RECENTLY issued a position statement on rising cancer drug prices. The statement, asserting that solutions to address the affordability of cancer drugs must also preserve patients’ access to care and foster innovation, analyzes a wide array of options and recommends that a panel of...

cost of care

ASCO Offers Path to Addressing Affordability of Cancer Drugs in New Position Statement

Today, ASCO issued a position statement aimed at contributing to the national dialogue on rising cancer drug prices. The statement, which asserts that any solutions must also preserve patients' access to care and foster innovation, analyzes a wide array of options and recommends that a panel of...

Clifford A. Hudis, MD, FACP, FASCO, Selected for Drexel 100

DREXEL UNIVERSITY has recognized the Chief Executive Officer of ASCO, Clifford A. Hudis, MD, FACP, FASCO, as a Drexel 100 member.  Created in 1992 to celebrate Drexel’s centennial, inductees to the Drexel 100 are university alums celebrated for their significant contributions to their respective...

ASCO Announces CancerLinQ Partnerships With the FDA and the NCI

CancerLinQ®, ASCO’s big data initiative to rapidly improve the quality of cancer care, is partnering with the U.S. Food and Drug Administration (FDA) and the National Cancer Institute (NCI) to study the real-world use of newly approved cancer treatments and speed and strengthen the...

Leader in International Clinical Trials, Robert L. Comis, MD, FASCO, Dies at 71

Robert L. Comis, MD, FASCO, Co-Chair of the ECOG-ACRIN Cancer Research Group, succumbed to a sudden illness at his home and died on May 10, 2017, at the age of 71. A giant in national and international clinical research since 1977, Dr. Comis is known as a champion of patient access to cancer...

Leader in International Clinical Trials, Robert L. Comis, MD, FASCO, Dies at 71

Robert L. Comis, MD, FASCO, Co-Chair of the ECOG-ACRIN Cancer Research Group, succumbed to a sudden illness at his home and died on May 10, 2017, at the age of 71. A giant in national and international clinical research since 1977, Dr. Comis is known as a champion of patient access to cancer...

ASCO CEO Reflects on His First Year in Office and What Is Ahead

June 27, 2017, marks the 1-year anniversary since Clifford A. Hudis, MD, FACP, FASCO, began his tenure as Chief Executive Officer of ASCO. With the launch of the national Cancer Moonshot and the changes in the White House and Congress, it has been a year of tremendous activity drawing on all of...

My Year of Living Wonderfully: 12 Months as ASCO President

EACH YEAR, the ASCO President chooses a theme for his or her term, which is not a trivial pursuit. Trying to think up something novel and catchy, yet not schmaltzy, is quite a challenge. However, in my year as Chair of the Scientific Program Committee for the 2010 ASCO Annual Meeting, then during...

ASCO Remembers Robert L. Comis, MD, FASCO

ASCO and the oncology community are deeply saddened by the loss of Robert L. Comis, MD, FASCO, who passed away on May 10, 2017, at the age of 71. Dr. Comis was a powerful voice in support of clinical trials, cooperative group research, and patient advocacy throughout his career. “Bob helped...

health-care policy

ASCO Applauds Congress for Providing Additional $2 Billion in NIH Funding

On May 1, Congress announced a bipartisan 2017 budget deal that contains a $2 billion increase in medical research funding for the National Institutes of Health (NIH), including $475 million more for the National Cancer Institute. The budget also maintains funding for cancer control programs at the ...

issues in oncology

How ASCO’s CancerLinQ Discovery™ Will Help Speed Research Advances and Improve Patient Outcomes

This past November, ASCO announced the launch of CancerLinQ Discovery™, a big data learning platform physicians and researchers can use to analyze highly curated, de-identified, real-world cancer care data sets to broaden their clinical knowledge about specific cancers and eventually improve...

Guidelines Planned on Management of Immunotherapy Side Effects: ASCO and NCCN to Collaborate on Development

Given the pace of advances in immunotherapy in recent years and physicians’ need to keep up with these developments, ASCO and the National Comprehensive Cancer Network® (NCCN®) have announced a joint collaboration to publish practical clinical guidance on the management of side effects caused by...

issues in oncology
health-care policy

The Path Forward for Clinical Pathways in Oncology

The year 2016 was a memorable one for oncology. In January, President Barack Obama announced the launch of the National Cancer Moonshot initiative, spearheaded by Vice President Joe Biden, which aims to accelerate cancer research. And in December, through bipartisan Congressional support, the 21st ...

ASCO and NCCN to Collaborate on Guidelines on Management of Immunotherapy Side Effects

ASCO and the National Comprehensive Cancer Network® (NCCN®) have announced a joint collaboration to publish practical clinical guidance on the management of side effects caused by immunotherapy. This novel collaboration aims to rapidly support improved quality of care for the growing number of...

health-care policy

Oncology Organizations Applaud Passage of the 21st Century Cures Act

On Tuesday, December 13, President Obama signed into law the 21st Century Cures Act, landmark legislation designed to improve and accelerate the pace of biomedical research in the United States. ASCO Chief Executive Officer Clifford Hudis, MD, FACP, FASCO, attended the White House signing ceremony ...

ASCO CEO Dr. Clifford Hudis Commends President Obama, Vice President Biden, and Congress During 21st Century Cures Act Signing Ceremony

On Tuesday, December 13, President Obama signed into law the 21st Century Cures Act, landmark legislation designed to improve and accelerate the pace of biomedical research in the United States. ASCO Chief Executive Officer Clifford Hudis, MD, FACP, FASCO, attended the White House signing ceremony...

Research Community Forum 2016 Annual Meeting: Using Collective Wisdom to Improve Cancer Research

The ASCO Research Community Forum held its 2016 Annual Meeting from September 25–26, at ASCO headquarters in Alexandria, Virginia. Nearly 100 physician investigators and research staff from all types of research sites across the United States attended the meeting. Each year, the ASCO Research...

Extending ASCO’s Influence Globally to Improve Patient Care

On June 27, 2016, Clifford A. Hudis, MD, FACP, FASCO, will begin his tenure as Chief Executive Officer of ASCO, succeeding Allen S. Lichter, MD, FASCO, who presided over the Society and the Conquer Cancer Foundation of ASCO since 2006. Dr. Hudis’ dedication to ASCO dates back more than 25 years...

In Celebration of a Remarkable Career at ASCO

In March, ASCO announced that Allen S. Lichter, MD, FASCO, was stepping down as Chief Executive Officer (CEO) at the end of June, ending his 10-year tenure as head of the Society and the Conquer Cancer Foundation of ASCO. Clifford A. Hudis, MD, FACP, Chief of Breast Medicine Service and Vice...

2016 Special Awards: Researchers and Scientists Recognized for Significant Contributions to Cancer Care

Researchers, patient advocates, and global oncology community leaders dedicated to enhancing cancer prevention, treatment, and patient care will be honored with ASCO’s highest honor, its Special Awards, during the 2016 ASCO Annual Meeting. Among this year’s awardees are a lung cancer luminary who...

Clifford A. Hudis, MD, FACP, Named ASCO’s Next CEO

Clifford A. Hudis, MD, FACP, Chief of the Breast Medicine Service, Vice President for Government Relations, and Chief Advocacy Officer at Memorial Sloan Kettering Cancer Center (MSKCC), and Professor of Medicine at Weill Cornell Medical College, has been named the next Chief Executive Officer...

Clifford A. Hudis, MD, FACP, Named ASCO’s Next CEO

Clifford A. Hudis, MD, FACP, Chief of the Breast Medicine Service, Vice President for Government Relations, and Chief Advocacy Officer at Memorial Sloan Kettering Cancer Center (MSKCC), and Professor of Medicine at Weill Cornell Medical College, has been named the next Chief Executive Officer (CEO) ...

Advertisement

Advertisement




Advertisement